# Uniprot activity

- Search for your protein: human glycyl-tRNA
  - Choose only reviewed, human proteins
  - What does "reviewed" mean?
  - Downloadthelistofproteins(UniprotIDs). Thistimepa yattention: Makesure you focus on your protein of interest.



- For the top entry (your protein of interest),
  - What is the UniProt ID?
    - P41250
  - note active site, binding site or other functionally important residues



### Note natural variants (Feature viewer)

#### Involvement in disease

The disease is caused by mutations affecting the gene represented in this entry. Contrary to the wild-type protein, CMT2D variants Gly-125 and Arg-294 strongly interact with NRP1. This interaction may compete out VEGFA binding and inhibits VEGFA-NRP1 signling which is essential for motor neuron survival, as suggested by experiments done in a mouse model. 

1 Publication

<u>Disease description:</u> A dominant axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. Related information in OMIM

Feature key	Position(s)	Description Actions	Graphical view	Length
Natural variant <sup>1</sup> (VAR_073187)	111	A $\rightarrow$ V in CMT2D; shows a reduction in aminoacylation activity.		1
Natural variant <sup>i</sup> (VAR_018718)	125	$E \rightarrow G$ in CMT2D; phenotype overlapping with DSMA-V; complements the defect of the wild-type gene in yeast; contrary to the wild-type protein, strongly binds to NRP1 and competes with VEGFA for NRP1-binding; displays slightly elevated aminoacylation activity over wild-type. $\  \  \  \  \  \  \  \  \  \  \  \  \ $		1
Natural variant <sup>i</sup> (VAR_073188)	200	$D \rightarrow N$ in CMT2D and HMN5A; shows a large reduction in aminoacylation activity. $\checkmark$ 2 Publications $\checkmark$		1
Natural variant i (VAR_074016)	200	D → Y in CMT2D.    ¶ 1 Publication ▼		1
Natural variant <sup>i</sup> (VAR_073189)	265	S → F in CMT2D and HMN5A; shows a large reduction in aminoacylation activity; demonstrates a change in the subcellular location pattern; does not associate with granules.   ② 2 Publications → Corresponds to variant dbSNP:rs1554337974   Ensembl, ClinVar.		1
Natural variant i (VAR_074017)	292	M → R in CMT2D.   ¶ 1 Publication ▼		1
Natural variant <sup>i</sup> (VAR_018720)	294	$G \rightarrow R$ in CMT2D; shows a large reduction in aminoacylation activity; does not impair transcription or translation or protein stability; contrary to the wild-type protein, strongly interacts with NRP1. $\checkmark$ 4 Publications $\checkmark$ Corresponds to variant dbSNP:rs137852643 Ensembl, ClinVar.		1
Natural variant <sup>i</sup> (VAR_073190)	298	$P \rightarrow L$ in CMT2D; shows a large reduction in aminoacylation activity; demonstrates a change in subcellular location pattern; does not associate with granules. $\bigcirc$ 2 Publications $\bigcirc$ Corresponds to variant dbSNP:rs137852648 Ensembl, ClinVar.		1
Natural variant <sup>i</sup> (VAR_073191)	334	I → F in CMT2D; shows a large reduction in aminoacylation activity; demonstrates a change in subcellular location pattern; does not associate with granules; unknown pathological significance.  ② 3 Publications Corresponds to variant dbSNP:rs1554338260 Ensembl, ClinVar.		1
Natural variant <sup>i</sup> (VAR_073193)		D → N in CMT2D; demonstrates no change in subcellular location pattern.    ¶ 1 Publication ▼  Corresponds to variant dbSNP:rs137852647  Ensembl, ClinVar.		1
Natural variant <sup>i</sup> (VAR_073195)	652	$G \rightarrow A$ in CMT2D; shows a large reduction in aminoacylation activity; demonstrates a change in subcellular location pattern; does not associate with granules. $\textcircled{\ }$ 2 Publications $\checkmark$		1

## Are these natural variants close to the active site in sequence?

- Yes! Some examples.....
- The original function of our protein is the transfer of glycine to the cognate tRNA. At position 299 is the Glycine binding site. Change from Proline to Leucine at position 298 as well as position 294 (Glycine → Arginine) apparently leads to a large reduction of the aminoacylation activity (which is the intermediate formed during the "glycine transfer"). This might be due to the fact that the protein structure changes so that the glycine may not be accessible anymore.

- Same for the second glycine binding site (position 350). The variant (I → F) at position 334 also reduces aminoacylation activity
- At position 583 is the ATP binding site. (glycine transfer is ATP dependent). The variant where G → A at position 652 also leads to a reduction of the aminoacylation activity. But in this case it is not that the transfer of glycine is inhibited/reduced (e.g. due to inaccessibility) but the site where ATP binds.
- Find out more about your protein. What is its biological function? What does it do?
- Catalyzes the ATP-dependent ligation of glycine to the 3'-end of its cognate tRNA, via the formation of an aminoacyl-adenylate intermediate (Gly-AMP) (PubMed: 17544401, PubMed: 28675565, PubMed: 24898252).
- GO terms give you information about molecular function, cellular component, biological process. You can read more about them here: http://geneontology.org/
- Report the GO terms for your protein.

### GO - Molecular function:

• ATP binding: GO:0005524

•

- bis(5'-nucleosyl)-tetraphosphatase (asymmetrical) activity: GO:0004081
- glycine-tRNA ligase activity: GO:0004820
- identical protein binding GO:0042802
- protein dimerization activity GO:0046983
- transferase activity: GO:0016740

### GO - Biological processi

- <u>diadenosine tetraphosphate biosynthetic process</u> GO: 0046983
- glycyl-tRNA aminoacylation GO: 0006426
- mitochondrial glycyl-tRNA aminoacylation GO: 0070150
- tRNA aminoacylation for protein translation GO: 0006418